In partnership with: EQT
The grand finale of EQT Impact Challenge 2026 at Hong Kong’s M+ Museum in September saw some of Asia’s most promising deep-tech founders tackling challenges across climate and health.
The initiative, backed by global investment firm EQT and its philanthropic arm EQT Foundation, provides young companies with crucial early-stage investment alongside access to a global network of industry experts, investors and mentors.
After a seven-month journey that attracted more than 200 applicants and almost 6,000 public votes, five finalists took to the stage.
Advent Gene Therapeutics, which was named this year’s winner, has received investment of €500,000 (US$560,000) from EQT Foundation. The AI-driven biotech start-up develops next-generation viral vectors which enable safer, more precise and effective delivery of genetic medicines.
Okosix, which develops biopolymers that can reduce the use of plastic, and C2iTech, which hopes to use laboratory-grown cells to support the treatment of lung cancer , were named runners-up. They have both received support from Central Cove Group, the family office of Jean Eric Salata, chair of EQT Group.
SCMP Live of the South China Morning Post was an organising partner of EQT Impact Challenge 2026.
Source: South China Morning Post
